JIJuan Manuel Igea

Juan Manuel Igea

*This is an algorithmically generated author record based on publicly available information.

Juan Manuel Igea has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • NavigAIT.me, a Digital Intervention to Improve Long‐Term Adherence in Allergen Immunotherapy: Design of a Multicentre Randomised Trial

    by Paula Méndez‐Brea, Eloína González‐Mancebo, Roberto Bravo Cabañas, Moises A. Calderón, Stephanie Dramburg, Carmelo Escudero, Itziar Eusebio‐Cartagena, Antonio Letrán, Ernesto Enrique, Margarita Tomás‐Pérez, et al.

    Summary: Evaluating the real‐life effectiveness of a new digital intervention to improve persistence in allergen immunotherapy (AIT). Assessing persistence, implementation, effectiveness and satisfaction with AIT in a randomised controlled prospective large‐scale trial.

  • Open Access

    A Multi-Compartment Cytological Approach to Severe Asthma Phenotyping: The BRISA Study (Biomedical Research in Severe Asthma)

    by Javier Domínguez-Ortega, Gabriela Leon-Zambrana, José Antonio Cañas, Ismael García-Moguel, Juan Manuel Igea, Marcela Valverde-Monge, María Luisa Caballero, Mar Gandolfo-Cano, Leticia De Las Vecillas, Santiago Quirce, et al.

    Background: Accurate inflammatory phenotyping in asthma remains challenging. Nasal cytology has emerged as a potential non-invasive tool to assess airway inflammation in asthma. However, its relationship with lower airway inflammation and systemic biomarkers remains unclear, particularly in severe asthma (SA). Objective: To evaluate whether a multi-compartment approach could improve the characterisation of type 2 inflammation and the relationship between nasal cytology, induced sputum, and systemic inflammatory biomarkers in patients with severe asthma. Methods: In this cross-sectional exploratory BRISA study, twenty-two patients with SA underwent nasal cytology by mucosal scraping, induced sputum analysis, and serum biomarker assessment (periostin, eosinophil cationic protein, thymic stromal lymphopoietin, dipeptidyl peptidase-4, and total IgE). Patients were stratified according to blood eosinophil count (BEC < 300 vs ≥ 300 cells/μL). Correlations between compartments and associations with clinical and inflammatory variables were analysed. Results: Higher blood eosinophil counts were associated with worse lung function, increased exacerbations, and higher serum periostin levels. Valid induced sputum samples were obtained in 16 patients: 7 eosinophilic, 3 neutrophilic, 2 mixed eosinophilic-neutrophilic and 4 paucigranulocytic. Nasal cytology predominantly showed limited agreement with induced sputum inflammatory phenotypes. Serum TSLP, DPP4, and IgE also showed an upward trend in patients with higher blood eosinophil counts, although these differences were not statistically significant. Correlation analysis demonstrated a significant positive association between sputum and blood eosinophils, as well as between blood eosinophils and serum periostin. A strong positive correlation was also observed between serum eotaxin and TSLP. Conclusion: Nasal cytology alone cannot replace induced sputum for inflammatory phenotyping in SA, although it may provide complementary information on upper airway inflammation. Among the evaluated systemic biomarkers, periostin emerged as the most consistent marker associated with blood eosinophilia, while other biomarkers showed only non-significant trends. Further studies are needed to validate the role of combined biomarkers in predicting airway inflammation.